Cathie Wood’s trades often read like a quiet manifesto – what she buys signals confidence, what she trims hints at fading faith. In the week ended Dec. 19, that message was clear. ARK Investment Management leaned harder into AI-led biotechnology and crypto, while paring back exposure to consumer tech and electric-vehicle heavyweights.
At the center of that shift sat Recursion Pharmaceuticals (RXRX). ARK snapped up more than 2.8 million RXRX shares, worth about $13.4 million, spread across ARK Genomic Revolution ETF (ARKG) and flagship ARK Innovation ETF (ARKK). The additions lifted Recursion to the No. 27 holding in ARKK and a top-10 position in ARKG. The Utah-based biotech is betting on artificial intelligence (AI) to radically shorten drug discovery timelines, a thesis that neatly mirrors Wood’s long-held view of innovation reshaping healthcare.
